LEXARIA BIOSCIENCE CORP. (LEXX) Operating Margin
- Operating margin · 12 months: Value -3973.16%; Formula and calculation Operating income / revenue. Period ending 2026-05-31..
Operating margin
Overview →Financial period ending 2026-05-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -3973.16% | Operating income / revenue. Period ending 2026-05-31. $-7.71M ÷ $194.00K × 100 ≈ -3973.16% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -7.71M USD | Operating Income (Loss) |
| Revenue | 194.00K USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 0.00 USD | Cost of Goods and Services Sold |
| Research and development | 4.00M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-05-31 | $-7.71M | $194.00K | $0.00 | $4.00M | (m) | -3973.16% |
| 2026-02-28 | $-9.46M | $368.00K | $0.00 | $5.75M | (m) | -2571.89% |
| 2025-11-30 | $-10.76M | $522.00K | $0.00 | $6.96M | (m) | -2062.00% |
| 2025-08-31 | $-11.88M | $705.92K | $2.72K | $8.24M | (m) | -1683.01% |
| 2025-05-31 | $-11.40M | $615.92K | $2.72K | $7.32M | (m) | -1850.10% |
| 2025-02-28 | $-9.39M | $525.92K | $2.72K | $5.18M | (m) | -1785.00% |
| 2024-11-30 | $-7.30M | $496.92K | $2.72K | $3.74M | (m) | -1469.99% |
| 2024-08-31 | $-5.75M | $464.28K | $4.82K | $2.36M | (m) | -1239.16% |
| 2024-05-31 | $-4.66M | $411.02K | $4.82K | $1.89M | (m) | -1134.78% |
| 2024-02-29 | $-5.32M | $404.73K | $17.57K | $2.96M | (m) | -1314.99% |
| 2023-11-30 | $-5.98M | $279.75K | $20.53K | $3.41M | (m) | -2136.81% |
| 2023-08-31 | $-6.53M | $226.21K | $31.50K | $3.67M | (m) | -2888.50% |
| 2023-05-31 | (m) | $340.79K | $72.75K | $3.52M | (m) | (m) |
| 2023-02-28 | (m) | $347.36K | $78.64K | $2.63M | (m) | (m) |
| 2022-11-30 | (m) | $342.99K | $82.07K | $2.21M | (m) | (m) |
| 2022-08-31 | $-7.38M | $255.40K | $71.84K | $1.84M | (m) | -2891.05% |
| 2022-05-31 | (m) | $175.27K | $50.90K | $1.93M | (m) | (m) |
| 2022-02-28 | (m) | $279.61K | $92.25K | $1.63M | (m) | (m) |
| 2021-11-30 | (m) | $440.96K | $116.44K | $1.53M | (m) | (m) |
| 2021-08-31 | (m) | $722.74K | $175.35K | $1.26M | (m) | (m) |
| 2021-05-31 | (m) | $825.46K | $168.14K | $891.60K | (m) | (m) |
| 2021-02-28 | (m) | $772.57K | $128.47K | $461.71K | (m) | (m) |
| 2020-11-30 | (m) | $669.87K | $156.00K | $471.87K | (m) | (m) |
| 2020-08-31 | (m) | $384.54K | $99.38K | $387.07K | (m) | (m) |
| 2020-05-31 | (m) | $375.93K | $101.23K | $480.22K | (m) | (m) |
| 2020-02-29 | (m) | $354.43K | $84.00K | $686.69K | (m) | (m) |
| 2019-11-30 | (m) | $262.48K | $28.59K | $566.22K | (m) | (m) |
| 2019-08-31 | (m) | $222.61K | $22.89K | $555.73K | (m) | (m) |
| 2019-05-31 | (m) | (m) | $10.89K | $607.73K | (m) | (m) |
| 2019-02-28 | (m) | (m) | $10.22K | $469.77K | (m) | (m) |
| 2018-11-30 | (m) | (m) | $21.24K | $479.44K | (m) | (m) |
| 2018-08-31 | (m) | $433.29K | $25.18K | $492.86K | (m) | (m) |
| 2018-05-31 | (m) | (m) | (m) | $310.13K | (m) | (m) |
| 2018-02-28 | (m) | (m) | (m) | $225.30K | (m) | (m) |
| 2017-11-30 | (m) | (m) | (m) | $157.32K | (m) | (m) |
| 2017-05-31 | (m) | (m) | (m) | $23.32K | (m) | (m) |
| 2017-02-28 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-11-30 | $-1.27M | (m) | (m) | $14.31K | (m) | (m) |
| 2016-08-31 | $-1.28M | (m) | (m) | $9.02K | (m) | (m) |
| 2016-05-31 | $-1.57M | (m) | (m) | $107.07K | (m) | (m) |
| 2016-02-29 | (m) | (m) | (m) | $107.02K | (m) | (m) |
| 2015-11-30 | $-2.00M | (m) | (m) | $100.40K | (m) | (m) |
| 2015-08-31 | $-1.98M | (m) | (m) | $146.47K | (m) | (m) |
| 2015-05-31 | (m) | (m) | (m) | $48.39K | (m) | (m) |
| 2015-02-28 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-11-30 | (m) | (m) | (m) | $48.04K | (m) | (m) |
| 2014-08-31 | $-1.56M | (m) | (m) | $0.00 | (m) | (m) |
| 2014-07-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-07-31 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |